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Genetic testing for pathogenic variants resulting in increased breast cancer 
susceptibility is a useful tool in the clinic when determining the medical management of 
individuals with family histories of breast cancer. Once a pathogenic variant has been 
identified, healthy biological relatives can be testing for the pathogenic variant, and 
carriers can benefit from preemptive medical or surgical risk reduction strategies. 
Eligibility for genetic testing can be complicated; incorporating ages of onset for cancer 
diagnosis (≤ 50 years, for most cancers), cancer incidence across multiple generations, or 
biological relatives with multiple diagnoses of primary cancers. Recent advancements in 
technology, notably next-generation sequencing (NGS) applications in the clinic, have 
allowed the detection of pathogenic variants in a selection or panel of genes. This 
increased clinical sensitivity has increased the ability to identify those at increased risk 
for cancer, as well as the need to understand the genes and variants involved.  
Missense substitutions constitute an appreciable fraction of the burden of 
pathogenic variants, but are difficult to interpret. Many missense analysis programs have 
been developed as tools to estimate the deleteriousness of variants. Gene panels for 
cancer susceptibility include genes with differing levels of associated risk. For breast 
cancer panels, the high-risk genes include BRCA1, BRCA2, PALB2, and TP53. Carriers 
of pathogenic variants in high-risk breast cancer susceptibility genes have clear 
guidelines for clinicians. In order to determine the percentage of women impacted by 
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pathogenic variants in moderate-risk breast cancer genes, variants in nine moderate-risk  
breast cancer susceptibility genes from previously published studies were graded for 
severity via frequency, protein location, and in silico predictions from Align-GVGD, 
MAPP, CADD, and Polyphen-2. Potentially pathogenic rare variants were grouped until 
an acceptable stratification for variants of uncertain significance (VUS) was established. 
We observed that 7.5% of early-onset breast cancer cases- versus 2.4% controls, were 
estimated to carry a medically actionable variant in at least one of the nine moderate-risk 
breast cancer genes.  
 Genes associated with hereditary breast and ovarian cancer (HBOC) and 
colorectal cancer (CRC) susceptibility have been shown to play a role in pancreatic 
cancer susceptibility. Germline genetic testing of pancreatic cancer cases could be 
beneficial for at-risk relatives with pathogenic variants in established HBOC and CRC 
genes. In pancreatic cancer cases ascertained at the Huntsman Cancer Hospital, but 
unselected for family history, 7.6-8.5% carried a variant that would alter the screening 
recommendations for at-risk relatives. A meta-analysis including additional published 
studies revealed that approximately 11.9% of unselected pancreatic cancer cases carry a 
pathogenic variant in HBOC or CRC susceptibility genes. The inclusion of both HBOC 
and CRC susceptibility genes in a panel test for pancreatic cancer cases finds a high 
enough percentage of carriers to rationalize genetic testing of these patients for HBOC 
and CRC susceptibility. 
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Genetic testing for pathogenic variants resulting in increased cancer susceptibility 
is a useful tool in the clinic when determining the medical management of individuals  
with family histories of cancer.1–4 The results from a genetic test can be used to  
rationalize a change in medical management. Medical management can be altered for  
earlier detection of a cancer through intensifying surveillance options and/or reducing the 
age of screening, or lower the risk of cancer incidence through measures such as  
preventive surgery.3,5 Once a pathogenic variant in a family has been identified, healthy  
biological relatives can be tested, and carriers can benefit from preemptive  
surveillance.3,5,6 As personalized medicine continues to evolve, genetic testing may be  
able to guide cancer treatments for carriers that develop cancer.7,8  
Eligibility for genetic testing is based primarily off of a family history for a  
specific, or a collection of specific cancers.1–4,9–14 Eligibility, then, can be complicated  
incorporating ages of onset for cancer diagnosis (≤ 50 years, for most cancers), cancer  
incidence across multiple generations, or biological relatives with multiple diagnoses of 
primary cancers.1–5,9,13,14 Because of the current criteria, inclusion is biased towards  
individuals who inherit pathogenic variants maternally, and complicated for those with  
limited family histories, such as those from small families or those that are adopted.15 
 
Recent advancements in technology, notably next generation sequencing (NGS)  
 
applications in the clinic, have  allowed the detection of pathogenic variants in a selection  
 
or panel of genes, rather than just a singular gene.16–20 This increased clinical sensitivity,  
 
i.e., the increased ability to detect more variants, has increased the ability to identify  
 
those at increased risk for cancer, but has also increased the need to understand the genes  
 
and variants involved.20–27 The increase in the amount of the genome screened increases  
 
the number of variants of uncertain significance (VUS).20–26 VUS are variants that have  
 
been identified in an individual, but have an unknown functional impact. VUS, then,  
 




1. Nonsense substitutions and frameshift indels. 
 
2. Large indels that alter one or more exons. 
 




4. Missense substitutions that fall at evolutionarily conserved sites in the protein. 
 
5. Nucleotide substitutions falling within the splice donor or splice acceptor. 
 
consensus sequences but outside of the core dinucleotides. 
 
6. Exonic substitutions that create strong splice donors or acceptors. 
 




Missense substitutions, nonsense substitutions located in the final exon of a  
 
protein, and in-frame indels are difficult to interpret, and routine medical management  
 
may not be appropriate under uncertain circumstances for VUS carriers. Many missense  
2
analysis programs have been developed as tools to estimate the deleteriousness of  
 
variants. Admittedly, many of these missense analysis programs have similar algorithms  
 
used in their labeling strategies.28 Still, these missense analysis programs might be used  
 
to distinguish subsets of variants with elevated probabilities of pathogenicity. When  
 
calibrated against observational data or else independently generated variant  
 
classifications, a prior probability score can be combined with clinical data to establish  
 
whether a variant is pathogenic, and, thereby, medically actionable.29–35       
 
Incidental findings are pathogenic variants identified in genes not related to the  
 
reason for ordering the sequencing, but still have medical utility. These are genes with  
 
clear enough guidelines for clinicians to influence medical management, even without a  
 
complete family history. Gene panels for cancer susceptibility include genes with  
 
differing levels of associated risk. For breast cancer panels, the standard high-risk genes  
 
BRCA1, BRCA2, and TP53 are generally included.3,36,37 BRCA1 and BRCA2 confer a 65- 
 
85% and 45-85% lifetime risk of breast cancer, respectively.38–40 TP53 increases risk to a  
 
wide spectrum of cancers. Carriers of pathogenic variants in high-risk breast cancer  
 
susceptibility genes are labeled by the American College of Medical Genetics (ACMG)  
 
as reportable as incidental findings.41–45  
 
PALB2 confers a similar high-risk of breast cancer, but is not yet labelled as a  
 
gene with reportable incidental findings.36,46–49 Moderate-risk breast cancer genes are  
 
those that confer only a 2-4 fold increase of risk for carriers.37,50–55 Many of these genes  
 
are newly identified and the lifetime risks of pathogenic variants, and the identification of  
 
pathogenic variants is not as readily available. ATM and CHEK2, both moderate-risk  
 
breast cancer genes, have recently been added into NCCN’s guideline of medically  
 
actionable genes with guidelines,1 but the surrounding medical management of carriers of  
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pathogenic variants in other moderate-risk genes is not clear.16,21 VUS are especially  
common for moderate-risk genes because missense substitutions have not been as  
extensively studied.53 Although the identification and addition of new breast cancer  
susceptibility genes is not a problem in and of itself, translating incomplete information 
into the clinic setting does result in confusion and possible mismanagement.17,20,26  
In order to determine the percentage of women impacted by pathogenic variants  
in moderate-risk breast cancer genes, preascertained variants in nine moderate-risk  
breast cancer susceptibility genes from previously published studies were graded for  
severity via frequency, protein location, and in silico predictions from Align-GVGD,  
MAPP, CADD, and Polyphen-2.56–65 Common variants (> 0.1% frequency) and those too 
internally intronic to be predicted to impact splicing were outgrouped as lacking  
pathogenic potential. Potentially pathogenic rare variants were placed into one of several  
groups. The first group contained variants that were considered clearly pathogenic:  
truncating and splice junction variants that were expected to trigger nonsense mediated  
decay. The second group contained variants with interpretations that were not as clear:  
rare missense substitutions, in-frame deletions, and last-exon protein truncating variants.  
This second group was further divided by in silico analysis of missense substitutions via  
the score of each missense substitution with each missense analysis program. Once an  
acceptable stratification for VUS was established, it was applied to real populations to  
estimate the number of carriers of pathogenic variants in moderate-risk breast cancer  
susceptibility genes.  
This same sample set of women were genotyped for 18 Breast Cancer Association 
Consortium (BCAC)-confirmed SNPs. Risk estimates from each SNP were combined to  
determine a final normalized polygene score (NPS) for each woman’s polygenotype.66  
4
These NPS were stratified to determine the subpopulation of carriers not of individual  
 




 The inclusion of moderate-risk breast cancer susceptibility genes increases the  
 
number of pathogenic variants identified.67 This increase in actionable test results could  
 
be high enough to expand the eligibility of genetic testing. Using the VUS stratification  
 
method mentioned above, unselected breast, ovarian, and pancreatic cancer cases were  
 
selected solely on their personal cancer diagnosis and family’s inclusion in the Utah  
 
Population Database.68 A panel consisting of 34 genes was used to identify known and  
 
potential medically actionable variants in order to estimate the percentage of carriers  
 
among cases alone. This was repeated with a 59 gene panel on additional pancreatic  
 
cancer cases, selected sequentially at the Huntsman Cancer Hospital.  
 
To sequence our panel genes, we used a barcode-then-pool strategy. In short,  
 
DNA is sheared through sonication and adaptors and barcodes are ligated onto the DNA  
 
fragments in subsequent steps. The barcoded genomic libraries are then pooled for  
 
subsequence capture, and super-pooled for sequencing. Generally, 30X coverage from  
 
paired-end reads is considered sufficiently deep to detect heterozygous positions, but we  
 
were concerned about the evenness of exon representation following targeted exon  
 
capture. Our goal, therefore, was to achieve 100X coverage per nucleotide in sequence  
 
coverage. Reads were mapped to the genome using GATK best practices.69 Both single  
 
nucleotide substitutions and short indels were extracted from the mapped reads. Since we  
 
were specifically expecting rare variants and common variants were irrelevant to our  
 
main analysis, variants were cross-referenced against dbSNP, the Thousand Genomes  
 
Project data, and ExAC.70–72 Variants with estimated allele frequencies greater than 0.1%  
5
in any population were set aside, and did not contribute to this study’s analyses of genetic  
 
susceptibility. Many of the “found” rare variants could have been screening artifacts.  
 
Variants with an increased probability of pathogenicity, were confirmed through sanger  
 
sequencing.73 Once the variants were confirmed in our unselected populations, they were  
 
combined into a meta-analysis with other studies to explore the proportions of the  
 






1. Develop a method of stratification of genetic markers to estimate the number of  
 
women carrying medically actionable breast cancer susceptibility variants outside  
 
of the high-risk spectra. 
 
a. Isolate subgroups of missense substitutions using in silico methods via  
 
pathogenicity prediction from missense analysis programs.  
 
b. Combine risk estimates from BCAC-confirmed SNPs and determine a  
 
polygenic score that delineates subgroups of women.  
 
2. Combine genotyping of clearly pathogenic variants with the developed  
 
stratification for VUS to estimate the number of unselected breast, ovarian, and  
 
pancreatic cancer cases with medically actionable variants identified from a panel  
 
of genes.  
 
a. Identify medically actionable variants in breast, ovarian, or colorectal cancer  
 
susceptibility genes in unselected breast and ovarian cancer cases. 
 
b. Identify medically actionable variants in breast, ovarian, or colorectal cancer  
 
susceptibility genes in unselected pancreatic cancer cases. 
 
c. Combine pancreatic cancer screening studies to estimate the number of  
6
pancreatic cancer cases carrying medically actionable variants in breast, 
ovarian, and colorectal cancer genes. 
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ABSTRACT
Background Moderate-risk genes have not been
extensively studied, and missense substitutions in them
are generally returned to patients as variants of
uncertain signiﬁcance lacking clearly deﬁned risk
estimates. The fraction of early-onset breast cancer cases
carrying moderate-risk genotypes and quantitative
methods for ﬂagging variants for further analysis have
not been established.
Methods We evaluated rare missense substitutions
identiﬁed from a mutation screen of ATM, CHEK2,
MRE11A, RAD50, NBN, RAD51, RINT1, XRCC2 and
BARD1 in 1297 cases of early-onset breast cancer and
1121 controls via scores from Align-Grantham Variation
Grantham Deviation (GVGD), combined annotation
dependent depletion (CADD), multivariate analysis of
protein polymorphism (MAPP) and PolyPhen-2. We also
evaluated subjects by polygenotype from 18 breast
cancer risk SNPs. From these analyses, we estimated the
fraction of cases and controls that reach a breast cancer
OR≥2.5 threshold.
Results Analysis of mutation screening data from the
nine genes revealed that 7.5% of cases and 2.4% of
controls were carriers of at least one rare variant with an
average OR≥2.5. 2.1% of cases and 1.2% of controls
had a polygenotype with an average OR≥2.5.
Conclusions Among early-onset breast cancer cases,
9.6% had a genotype associated with an increased
risk sufﬁcient to affect clinical management
recommendations. Over two-thirds of variants conferring
this level of risk were rare missense substitutions in
moderate-risk genes. Placement in the estimated
OR≥2.5 group by at least two of these missense
analysis programs should be used to prioritise variants
for further study. Panel testing often creates more heat
than light; quantitative approaches to variant
prioritisation and classiﬁcation may facilitate more
efﬁcient clinical classiﬁcation of variants.
INTRODUCTION
For the last 15+ years, most clinical cancer genetics
involving predisposition to breast (and ovarian)
cancer have been driven by mutation screening of
BRCA1 and BRCA2. For these two genes, the ratio
of truncating and splice junction variants (T+SJV)
to pathogenic rare missense substitutions (rMS) is
about 10:1,1 2 fostering a view among clinical
cancer geneticists that rMS are only a minor part of
the spectrum of breast cancer predisposing
variants.
Following the discoveries of BRCA1 and BRCA2,
many additional genes have been identiﬁed as
breast cancer susceptibility genes. A prominent
group of these are referred to as moderate-risk sus-
ceptibility genes because protein truncating variants
and severely dysfunctional missense substitutions in
them appear to confer, on average, twofold to ﬁve-
fold increased risk of breast cancer. This magnitude
of increased risk is less dramatic than that con-
ferred by most pathogenic alleles in the high-risk
genes BRCA1, BRCA2 and PALB2, but potentially
high enough to inﬂuence the medical management
of carriers.3–6 Beyond the moderate-risk genes,
many common SNPs have been identiﬁed as
markers for slightly increased breast cancer risk.7–9
A challenge posed by these modest-risk SNPs is
that, individually, they do not confer enough risk
to inﬂuence the medical management of a carrier,
but considered as an ensemble they may.
In our previously published case–control muta-
tion screening studies of ATM, CHEK2, MRE11A,
NBN, RAD50, RAD51, RINT1 and XRCC2,10–15
we repeatedly found, albeit with some variations in
the methodology, that the summed frequency of
predicted deleterious missense substitutions
exceeded that of protein truncating variants. This
study used the same ethnically diverse sample of
1297 breast cancer cases and 1121 controls, nega-
tive for pathogenic variants in BRCA1, BRCA2 or
PALB2 (table 1). Here, we added BARD1 mutation
screening data to the original gene-by-gene analyses
and applied consistent analytic models across the
rare variants from all nine genes. Setting an
OR≥2.5 as a threshold for clinical signiﬁcance, we
estimated the scores from the missense substitution
analysis programs Align-GVGD,16 CADD,17
MAPP18 and PolyPhen-219 required to identify a
group of missense substitutions that reach an
average OR≥2.5. These results were used to deter-
mine the proportion of cases and controls carrying
a potential risk-conferring rMS. We also explored a
combined evaluation of 18 Breast Cancer
Association Consortium (BCAC)-conﬁrmed
Open Access
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modest-risk SNPs as a polygene, compared predicted to empiric-
ally observed ORs and estimated the prevalence of genotype
combinations across these 18 SNPs with an average OR≥2.5.
Our data set is unique in that the moderate-risk gene mutation
screening and SNP genotyping were performed on the same
subjects, giving us the opportunity to compare prevalence of the
OR≥2.5 threshold across T+SJV and OR≥2.5 groupings of
rMS or normalised polygene score (NPS).
MATERIALS AND METHODS
Subjects
Patients were selected from women systematically recruited by
population-based sampling by the Australian, Northern
Californian and Ontarian sites of the Breast Cancer Family
Registry (BCFR). Patients were recruited between 1995 and
2005. The selection criteria for cases (N=1297) were diagnosis
at or before age 45 years and self-reported race/ethnicity plus
grandparents’ country of origin consistent with Caucasian, East
Asian, Hispanic/Latino or Recent African racial or ethnic heri-
tage.20 The controls (N=1121) were frequency matched to
cases within each centre on racial or ethnic group, with age at
selection not more than ±10 years difference from the age
range at diagnosis of the patients systematically recruited from
the same centre.
Mutation screening and SNP genotyping
Mutation screening was as described previously10–15 and is
included in online supplementary methods, as is SNP genotyp-
ing. The following methods focus on the analysis of missense
substitutions and of the ensemble of 18 modest-risk SNPs.
Allele frequency threshold
Following our allele frequency analysis of ATM, BRCA1,
BRCA2 and CHEK2 from Damiola et al,12 we applied a minor
allele frequency (q) threshold of ≤0.1%, based on exome
variant server and 1000 genomes project allele frequency data
that are independent of this study’s mutation screening, for all
variants of the eight genes in which biallelic truncating variants
are often either embryonic lethal or else cause a highly dele-
terious phenotype from the ataxia telangiectasia/Fanconi
anaemia spectrum. Biallelic CHEK2 carriers are superﬁcially
healthy, and our analysis suggested a cut-off of q<0.32% for
that gene.12
In silico missense substitution scoring
Align-GVGD (agvgd.iarc.fr/agvgd_input.php) and MAPP (mendel.
stanford.edu/SidowLab/downloads/MAPP/index.html) require
user-supplied protein multiple sequence alignments (pMSAs) to
score missense substitutions; both compare the physicochemical
features of the missense residue to the physicochemical range of
variation at the relevant position in the pMSA to calculate their
scores. Align-GVGD produces a score with seven discrete grades
from C0 (most likely neutral) to C65 (most likely deleterious).
MAPP, which additionally requires a phylogenetic tree detailing the
evolutionary relationships and distances between the organisms
with sequences represented in the pMSA, outputs a continuous
variable, the MAPP score.
For programs that require a user-generated pMSA, it has been
suggested that the pMSA for each gene needs enough variation
to average at least three amino acid substitutions per position
(3S/P).21 For each gene, we created an initial pMSA containing
the human sequence and 13 additional orthologs. To maintain
harmony across the pMSAs, orthologs were sampled from a
phylogenetically similar set of organisms ranging from a non-
human primate (Macaca mulatta) to the non-chordate deuteros-
tomate Strongylocentrotus purpuratus (see details in online sup-
plementary methods).
Ortholog sequences downloaded from GenBank were aligned
using the expresso extension of T-Coffee to create the initial
pMSA.22 23 The initial alignment was checked by hand in
Geneious V.7.1.4 ( http://www.geneious.com) for anomalies that
might be attributed to gene model errors rather than actual
Table 1 Distribution of cases and controls by age, race/ethnicity and study centre
Case–control mutation screening for rare variants in
nine moderate-risk genes Case–control SNP genotyping for 18 BCAC SNPs
Distributions Case % Control % Case % Control %
Age range, years
≤30 106 8.2 67 6.0 97 7.8 61 5.8
31–35 319 24.6 171 15.3 300 24.3 157 14.9
36–10 433 33.4 238 21.2 409 33.1 220 20.8
41–45 439 33.9 203 18.1 430 34.8 183 17.3
46–50 0 0 230 20.5 0 0 225 21.3
51–55 0 0 212 18.9 0 0 211 20.0
Race/ethnicity
Caucasian 840 64.8 967 86.3 788 63.8 904 85.5
East Asian 202 15.6 71 6.3 193 15.6 70 6.6
Latina 158 12.2 47 4.2 158 12.8 47 4.5
Recent African Ancestry 97 7.5 36 3.2 97 7.9 36 3.4
Study centre
BCFR-Australia 588 45.4 522 46.6 551 44.6 472 44.7
BCFR-Canada 299 23.1 463 41.3 284 23.0 499 42.5
BCFR-Northern California 410 31.6 136 12.1 401 32.4 136 12.9
Total 1297 1121 1236 1057
Subjects were excluded from mutation-screening if performance was poor; percentage data are the total number of cases on control DNA in the category indicated that met the
mutation-screening quality control standards.
BCAC, Breast Cancer Association Consortium; BCFR, Breast Cancer Family Registry.
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sequence divergence. Potential anomalies were corrected by ref-
erence to, and gene reprediction from, genomic DNA sequence
available on the UCSC genome browser (http://genome.ucsc.
edu).
Routines from the PHYLIP package (V.3.69),24 constrained
using the known phylogeny of the species included in our align-
ments, were used to estimate substitutions per position within
each alignment and to calculate the distance matrices required
by MAPP. The complete alignments, phylogenetic trees and dis-
tances are available upon request.
PolyPhen-2 (genetics.bwh.harvard.edu/pph2/)25 and CADD
(cadd.gs.washington.edu/)17 operate without user-supplied
alignments. PolyPhen-2 uses a combination of internally gener-
ated pMSAs, functional annotations and structural information
to evaluate missense substitutions;19 we used its output variable
‘pph2_prob’ as a continuous variable score. CADD uses a series
of 63 gene annotations, combined through a support vector
machine linear kernel, to deﬁne a PHRED-like score (their
‘scaled C-score’) for all possible single-nucleotide substitutions
and small insertion–deletion mutations to the human
genome.17
Although CADD has a built-in method for short indels, the
other missense analysis programs do not. For Align-GVGD,
MAPP and PolyPhen-2, nonsense substitutions in the ﬁnal exon
and non-frameshift indels received the score of the most severe
missense substitution possible in the affected interval. Variant
pathogenicity scores are summarised in online supplementary
table S1.
Statistics
To assess evidence of risk from the case–control frequency dis-
tribution of T+SJV and rMS, we constructed a table with one
entry per subject; the variants per subject; and annotations for
whether the variant was in a key functional domain (see online
supplementary table S2), its frequency, as well as study centre,
case–control status, race/ethnicity and age for the subject.
In-frame deletions (IFDs) were treated as rMS. For the subjects
who carried more than one rare variant of interest, only the
most deleterious score was considered. We then divided the sub-
jects into groups: a reference group of non-carriers and carriers
of common variants (only), carriers of rMS not in a functional
domain, carriers of rMS in a key functional domain divided
into two groups via score and carriers of T+SJVs. For each of
the four rMS analysis programs, we toggled the program’s
severity score from a very relaxed to a very stringent value. We
repeatedly estimated two ORs as the stringency increased: the
OR for subjects that carried one or more rMS at or above the
score (and no T+SJV), and the OR for subjects who carried an
rMS that was below the score (and carried neither a T+SJV nor
a higher scoring rMS). From this analysis, we determined a
threshold severity score for each program at which subjects car-
rying an rMS at or above the threshold had an average
OR≥2.5.
For the 18 SNP polygene, we created a polygenic risk score
(PRS) by multiplying together the appropriate published OR
estimate from each individual SNP genotype.7 9 26 27 The geo-
metric mean of the PRS of the controls was used to normalise
the PRS into an NPS. Because risk estimates from Caucasian
populations may not be applicable to women from other race/
ethnicities, we gave each non-Caucasian subject a race/ethnicity-
speciﬁc risk estimate derived from the population of the
subject,26 28–30 and normalised each race/ethnicity separately.
Risk estimates of rs1045485 could not be found for the
non-Caucasian subjects in this study, so the risk estimate based
on Caucasian populations was used for all race/ethnicities.
In instances where a Latina-speciﬁc risk estimate could not be
found, we used the average between Caucasian and East Asian
race/ethnicities. To determine the correlation between NPS and
the observed OR, we grouped the subjects into a series of 10
contiguous bins based on percentile, using the central quintile
(40–60 percentile) as the reference group. We treated groups
outside of the reference as categorical variables for OR calcula-
tions. For the threshold analysis, we used the same reference
group and adjusted the NPS threshold until the group contain-
ing scores above the set threshold had an OR≥2.5.
For the regressions, NPS was treated as the independent vari-
able and the resultant OR of each group as the dependent vari-
able weighted to the number of individuals in each group,
excluding subjects in the middle quintile. p Values were found
by testing the regression coefﬁcient equal to 0 or 1. To combine
the risk estimates from the rMS and NPS, we multiplied the
NPS and OR from the rMS.
All analyses were performed using multivariable uncondi-
tional logistic regression using Stata V.12.1 software (StataCorp,
College Station, Texas, USA). Adjustments were made for race/
ethnicity and study centre, unless otherwise noted.
RESULTS
Initial evaluation of rare variants
From mutation screening of 1297 cases and 1121 controls, we
observed 22 T+SJV, 9 IFDs and 196 rMS with minor allele fre-
quencies <0.32% for CHEK2 and <0.1% for the remaining
genes. T+SJVs falling before the ﬁnal exon were considered
pathogenic and were associated with an OR of 3.32 (p=0.0023,
table 2). Nonsense mutations located in the ﬁnal exon were con-
sidered as IFDs.
The National Comprehensive Cancer Network (NCCN) and
the American College of Radiology (ACR) recommend screen-
ing beginning at age 30 years and offering breast MRI in add-
ition to mammograms for women with a ≥20% lifetime breast
cancer risk.31 32 The American Cancer Society (ACS) recom-
mends breast MRI for women with a 20–25% or greater life-
time risk.33 In the USA, the lifetime risk of a woman to develop
breast cancer is estimated to be 12.3%;34 however, this ﬁgure is
an overestimate for our purposes because it includes women
who are at high risk because of inherited mutations in genes
such as BRCA1 or BRCA2, or very strong family history. For a
woman with minimal risk factors, for example, age at menarche
≥14 years, ﬁrst childbirth at age ≤20 years and no family
history, the Gail model35 and Tyrer–Cuzick model36 suggest a
lifetime risk of 6.9% and 11% for developing breast cancer,
respectively. If we assume that the average of these two estimates
(9%) is approximately correct, carriage of a genotype conferring
a 2.5-fold increase of risk, even in this low-risk population,
would result in a lifetime risk estimate exceeding the NCCN,
ACR and American Cancer Society (ACS) medically actionable
threshold of a 20% lifetime risk. Subject to formal variant classi-
ﬁcation, carriers may then qualify, under current recommenda-
tions, for early mammography and/or enhanced screening with
breast MRI. We note that threshold for intensiﬁed screening
may be higher in other countries.
Considering all rMS as a group, we obtained a risk estimate
that was elevated but that did not reach an OR≥2.5 threshold
(OR=1.42, p=0.0091, table 2). We focused our analyses of
rMSs to those that are relatively likely to impact key functions.
This grouping included all of the rMS from the relatively small
proteins encoded by CHEK2, RAD51, RINT1 and XRCC2.
Noting the structural similarity between BARD1 and BRCA1,
368 Young EL, et al. J Med Genet 2016;53:366–376. doi:10.1136/jmedgenet-2015-103398
Cancer genetics
16
and that BRCA1 pathogenic rMS are so far only known from
the RING and BRCT domains,37–40 we limited analyses of
BARD1 rMS to RING and BRCT domain substitutions. For the
relatively large proteins encoded by ATM, MRE11A, NBN and
RAD50, we focused analyses of rMS on the same key functional
domains speciﬁed in our prior publications (see online supple-
mentary table S2).10 12 We observed 140 rMS and IFDs in key
functional domains (OR 1.94, p=5.1×10−05, table 2), which
still did not reach an OR≥2.5 threshold.
Grouping rMS to estimate risk and carrier rates
To deﬁne a higher-risk subset of rMS, we focused the next ana-
lyses on the three established moderate-risk genes: ATM,
CHEK2 and NBN.41 There is no fully accepted method for rMS
analysis. Instead of introducing a new method for variant classi-
ﬁcation, we used four existing missense analysis programs,
Align-GVGD, CADD, MAPP and PolyPhen-2,16–18 25 to assign
severity scores to the key domain rMS from these genes.
Align-GVGD was selected because its scores contribute to deter-
mination of prior probabilities of pathogenicity for key domain
missense substitutions in BRCA1 and BRCA2,2 MAPP and
PolyPhen-2 because of their strong performance in our recent
analyses of mismatch repair protein missense substitutions,42
and CADD because of its reported ability to prioritise variants
across functional categories and effect sizes.17 For variant evalu-
ation, we adjusted our pMSAs to two depths: human through
platypus (mammals only), and human through the organism
required for 3S/P for each individual gene. Receiver operating
characteristic (ROC) curves were generated for each method
and depth (if applicable). Area under the curve (AUCs) were
similar for all methods (see online supplementary table S3 and
supplementary ﬁgure S1). The correlations between the mis-
sense analysis programs were highest between Polyphen-2 and
CADD (R2=0.56), but the R2 for any combination of missense
analysis programs was never >0.8, so none of the missense ana-
lysis programs were dropped from further analysis (see online
supplementary table S4).
We then toggled the severity score for each of the four pro-
grams to ﬁnd the lowest score where the OR for key domain
rMS above the score reached at least 2.5 (ﬁgure 1A–D). The
thresholds at which each of the four rMS analysis programs
reached OR≥2.5 for key domain rMS were above a score of
11 for MAPP when using pMSAs consisting of organisms
from human through 3S/P, C35 for Align-GVGD when using
pMSAs consisting of organisms from human through 3S/P, 23
for CADD and 0.9 for PolyPhen-2 (see online supplementary
table S5). It was interesting that neither Align-GVGD nor
MAPP was able to achieve an OR≥2.5 with a pMSA that con-
sisted only of mammals (human through platypus). It appears
that these sequences, although generally more complete than
those from more distant organisms, do not offer adequate
variation to stratify variants. Examining the variants that were
placed in the OR≥2.5 category by multiple missense analysis
programs, we found that an overlap of at least two of the mis-
sense analysis programs resulted in a classiﬁcation of variants
with an OR≥2.5 (OR 2.59, p=0.0044; online supplementary
table S6).
Applying the score thresholds determined from the
ATM-CHEK2-NBN group to the key domain rMS observed in
the remaining six less established moderate-risk genes, rMS ORs
for the BARD1-MRE11A-RAD50-RAD51-RINT1-XRCC2 group
ranged from 2.41 (p=0.0078) using PolyPhen-2 to 4.86
(p=0.0129) using Align-GVGD (data not shown). We also
found that concordance between at least two of the missense
analysis programs resulted in a grouping of rMS with an
OR≥2.5 (OR 4.90, p=0.0012; online supplementary table S6).
Table 2 Combined OR estimates from case–control mutation screening of nine moderate-risk genes
Analysis Distinct variants Control % Case % Adjusted OR* CI p Value
Non-carrier 148 998 89.0 1094 84.4 Reference
Carrier of truncating or splice junction variant 22 9 0.8 27 2.1 3.31 1.53 to 7.16 2.36×10−3
Rare missense substitution analyses
Carrier of rare missense substitution 205 114 10.2 176 13.6 1.42 1.09 to 1.84 8.70×10−3
Carrier of key domain rare missense substitution 140 65 5.8 136 10.5 1.94 1.41 to 2.67 5.11×10−5
Carrier of non-key domain rare missense substitution 65 49 4.4 40 3.1 0.74 0.48 to 1.16 0.1926
Key domain rMS: MAPP
rMS<11 63 39 3.5 58 4.5 1.47 0.95 to 2.26 0.0818
rMS≥11 77 26 2.3 78 6.0 2.63 1.65 to 4.21 5.32×10−5
Key domain rMS : Align-GVGD
rMS<C35 93 54 4.8 87 6.7 1.58 1.09 to 2.27 0.0146
rMS≥C35 47 11 1.0 49 3.8 3.62 1.84 to 7.13 2.03×10−4
Key domain rMS : CADD
rMS<23 97 50 4.5 88 6.8 1.66 1.14 to 2.41 0.0082
rMS≥23 43 15 1.3 48 3.7 2.87 1.57 to 5.26 6.40×10−4
Key domain rMS : PolyPhen-2
rMS<0.9 61 37 3.3 55 4.2 1.50 0.96 to 2.34 0.0752
rMS≥0.9 79 28 2.5 81 6.3 2.49 1.58 to 3.92 7.88×10−5
Overlap of missense analysis programs
One or more 89 34 3.0 93 7.2 2.37 1.57 to 3.60 4.56×10−5
Two or more 65 18 1.6 70 5.4 3.18 1.85 to 5.46 2.68×10−5
Three or more 45 14 1.2 52 4.0 3.27 1.77 to 6.04 1.51×10−4
All four 19 2 0.2 20 1.5 8.61 1.96 to 37.81 4.35×10−3
Total 375 1121 1297
*Adjusted for race/ethnicity and study centre.
rMS, rare missense substitutions.
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Having established that the thresholds identiﬁed with the
ATM-CHEK2-NBN group were able to extract OR≥2.5 group-
ings from the remaining six genes, we used these thresholds to
evaluate the proportions of cases and controls with above-
threshold variants across the nine-gene ensemble (table 2). We
found that 3.7–6.3% of cases and 1.0–2.5% of controls carried
an above-threshold key domain rMS. Considering only the key
domain rMS that were placed in an OR≥2.5 grouping by more
than one of the missense analysis programs (ﬁgure 1E,F), con-
cordance between two or more missense analysis programs was
associated with an OR≥2.5 (OR 3.18, p=2.68×10−5), affecting
5.4% of cases and 1.6% of controls (table 2). These results are
comparable to other studies, but include data from controls.43–45
Comparing the proportion of above-threshold key domain rMS
carriers to T+SJV carriers, rMS carriers appear to outnumber T
+SJV carriers by a ratio of about 2.5:1.
Asking whether the results reported here are robust to the
loss of any one gene from the less established moderate-risk
gene set, we performed a series of analyses in which the geno-
type information of one of the genes was dropped and then
the OR, rMS to T+SJV ratio, and carrier percentage was
re-determined for the rMS from the remaining eight genes. We
observed that, in each subset of eight genes, 3.0–5.9% of cases
and 0.8–2.7% of controls were carriers of a variant from the
above-threshold grouping, with a ratio of rMS to T+SJVs
consistently over 1.6:1 for cases (see online supplementary
table S7).
Common SNP-based polygene scores and above-threshold
carrier rates
Generally, individual modest-risk SNPs do not confer enough
risk to impact clinical practice. An attractive method for using
SNPs in a clinical setting is to combine the risk estimates from
multiple SNPs. Indeed, a recent large study combined risk esti-
mates from 77 SNPs and found ORs≥2.5 at and above the 99th
percentile of the combined scores.9 We genotyped 18
BCAC-conﬁrmed SNPs on the same subjects from the case–
control mutation screening phase of this study (table 1). Using
per-allele ORs from recent large studies,7 26 28–30 we treated the
SNPs as a polygene and created an NPS for each subject (see
online supplementary table S8 and ﬁgure 2A).
To determine how closely the NPS predicted OR, we grouped
the NPS scores into deciles and compared the mean NPS of each
decile to its observed OR. With all subjects grouped together,
the NPS correlated highly with the observed OR (coeff.
=0.9232, R2=0.70, p=0.0060) (ﬁgure 2B). Evaluating each
race/ethnicity individually, Caucasians were the only group to
achieve signiﬁcance (coeff.=0.9835, R2=0.81, p=0.0014)
(ﬁgure 2C, data not shown), likely due to small sample sizes of
the non-Caucasian groups. We also tested the alternate
Figure 1 Observed OR and thresholds for each missense substitution analysis program. The observed OR for the carriers of key domain rare
missense substitutions (rMS) of both the ‘above’ and ‘below’ groups for each severity threshold tested with (A) PolyPhen-2, (B) CADD, (C) MAPP and
(D) Align-GVGD, adjusting for race/ethnicity and study centre for just the combined ensemble of ATM, CHEK2 and NBN. Vertical lines are indicative
of the threshold for which the observed OR≥2.5. (E) A four-way Venn diagram detailing the number of rMS for which CADD, PolyPhen-2,
Align-GVGD and MAPP placed in the ‘above threshold’ group for key domain rMS observed in all nine moderate-risk genes. (F) A four-way Venn
diagram detailing the number of individuals for which CADD, PolyPhen-2, Align-GVGD and MAPP were placed in the ‘above threshold’ group for key
domain rMS observed in all nine moderate-risk genes. Mammals=score obtained from using protein multiple sequence alignments (pMSA)
containing sequences from human through platypus; 3S/P=scores are from gene-speciﬁc 3S/P depth pMSAs.
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hypothesis, NPS=observed OR, and did not observe a signiﬁ-
cant difference (p=0.75 and 0.93 for all subjects and
Caucasians, respectively).
Using the NPS, how many women are at a medically action-
able risk? Using an approach analogous to that applied to the
key domain rMS, we toggled the NPS to ﬁnd the lowest score
where the observed OR for the group of subjects with NPS
above the score exceeded 2.5 (ﬁgure 2D–E). From the data,
2.1% of cases and 1.2% of controls carry a combination of
SNPs such that they have a polygene score associated with an
average OR≥2.5 (table 3). Limiting the analysis to Caucasians,
we found that 3.2% of cases and 1.3% of controls have an NPS
associated with an average OR≥2.5.
To explore the possibility of integrating gene mutation screen-
ing with SNP genotyping, we tested for interactions between
carriage of an OR≥2.5 rare variant (combining T+SJVs and
above-threshold rMS into a single group) and the NPS. In these
tests, the interaction term never approached signiﬁcance
(p=0.52, 0.82, 0.51 and 0.96 for analyses with rMS scored by
Align-GVGD, CADD, MAPP and PolyPhen-2, respectively).
Accordingly, as the multiplicative OR model does appear to
apply to combinations of rare variants from these nine genes
with the NPS, we isolated the subjects who carried a rare
variant in the OR≥2.5 category and multiplied the OR esti-
mated from their rMS or T+SJV with their NPS. These com-
bined ORs varied from ∼1.0 to >5.0 (ﬁgure 3).
DISCUSSION
Neither pathogenic alleles in moderate-risk breast cancer suscep-
tibility genes nor individual modest-risk breast cancer-associated
SNPs confer the magnitude of risk of early-onset breast cancer
conferred by pathogenic alleles in high-risk genes such as
BRCA1 and BRCA2. Nonetheless, under a generalised under-
standing of NCCN, ACR and ACS guidelines, a ≥2.5-fold
increased risk of breast cancer is high enough to impact the
medical management of otherwise healthy carriers. Across the
nine moderate-risk susceptibility genes examined here, two
classes of sequence variants meet or exceed this 2.5-fold risk
threshold. 2.1% of cases carried a T+SJV, and these were asso-
ciated with an OR of 3.32 (p=0.0023). Each of the four mis-
sense substitution analysis programs that we evaluated was able
to deﬁne a set of key functional domain rMS that reached the
OR≥2.5 threshold. 5.4% carried an rMS that two or more of
the programs agreed was above the threshold, and this group of
rMS was associated with an OR of 3.18 (p=2.68×10−5). In
Figure 2 The normalised polygene score (NPS): distribution, NPS-OR correlation and threshold for medically actionable. (A) NPS distribution for all
subjects. Comparison of observed OR and NPS for each decile for (B) all subjects and (C) only Caucasians, with the corresponding equations derived
from linear regressions, excluding the central quintile. The observed OR when dividing subjects based on NPS, using the middle quintile as reference
for (D) all subjects and (E) only Caucasians, adjusting for race/ethnicity and study centre. Vertical lines are indicative of the threshold for which the
observed OR≥2.5, as well as the 1, 5, 95 and 99 percentiles. Bubble sizes are proportional to the number of subjects in each decile.
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addition, 2.1% of cases carried an above-threshold SNP poly-
gene genotype.
Whether focusing on the conﬁrmed moderate-risk genes
ATM, CHEK2 and NBN or looking at all nine genes, the ratio
of carriers of T+SJV to above-threshold key domain rMS was
in the range of 1:2–1:3. This ﬁnding is different than the ∼10:1
ratio observed in BRCA1/2; the preponderance of above-
threshold rMS in these moderate-risk genes is much more rem-
iniscent of the situation withTP53.5 Because most rMS observed
during clinical testing of these moderate-risk genes would be
returned as variants of uncertain signiﬁcance (VUS) in test
reports, the relatively high proportion of above-threshold rMS
reported here creates a challenge for test interpretation. During
clinical counselling, to alleviate patient distress, observations of
VUS rMS, especially in moderate-risk genes, are often down-
played as of minimal signiﬁcance—‘normalised’. However, at
least for the nine genes that we examined, normalising the rMS
amounts to disregarding approximately 2/3 of sequence variants
with OR≥2.5 detectable by the genetic tests.
Within the logical structure of the analyses presented here,
the OR≥2.5 threshold applied to rMS and SNP polygene
groupings was a device used to align the analyses with current
patient management standards. A consequence is that the OR
point estimates reported for those groupings in tables 2 and 3
are circularly dependent on the threshold selected.
Nonetheless, the following four key results are independent to
the circular logic underlying those OR point estimates: (i) the a
priori existence of groupings with OR≥2.5; (ii) the p values
associated with those groupings; (iii) the ratios of subjects with
T+SJVs, rMSs with OR≥2.5 and SNP polygene with OR≥2.5;
and (iv) the frequencies among controls and early-onset cases
of individuals with a genotype falling into one of these group-
ings. These ﬁndings all correspond to open, medically relevant
questions.
Although we did not accompany this study with functional
assays, a yeast complementation assay applied to 25 CHEK2
missense substitutions included applicable Align-GVGD and
PolyPhen-2 scores.46 Among the six rMS with Align-GVGD and
PolyPhen-2 scores meeting our severity criterion, the average
activity was −0.062 (SD=0.027) in an assay where the internal
wild-type and dysfunctional variants were given scores of 1.00
and 0.00, respectively. In contrast, the average score among the
19 rMS not meeting our concordant severity criterion was
+0.472 (SD=0.388), resulting in a p value of 1.12×10−5
against the hypothesis that the two groups have the same mean
activity. Moving forward, it will become important to develop
methods that combine patient observational data with in silico
and functional assay results towards clinical classiﬁcation of
these rMS. Such methods may leverage the Bayesian classiﬁca-
tion framework already developed for rMS in BRCA1, BRCA2,
MLH1, MSH2, etc.37 47 48
One weakness of this study is that it focuses on early-onset
cases using a data set that already contributed either to associ-
ation of rMS in these genes with breast cancer susceptibility
(ATM, CHEK2),10 11 or susceptibility to breast cancer in general
(MRE11A, NBN, RAD50, RINT1, XRCC2).12 14 15 While the
impact on the overall results of a possible false association for
one or another of the genes is addressed by the leave-one-out
analysis, the possibility remains that the ORs that we report are
systematically inﬂated either because this was a study of
early-onset cases or because of winner’s curse.41 These issues
were partly ameliorated in two ways: (i) an OR≥2.5 grouping of
rMS could be isolated by each of the four rMS analysis pro-
grams that we used, and (ii) the group of women that can
beneﬁt most from early or intensiﬁed breast cancer screening is
primarily those at risk of early-onset breast cancer—largely, the
group of women from which the cases used in this study are
drawn. Looking forward, the ratio of the above-threshold rMS
to T+SJV can be re-evaluated in case–control studies, but accur-
ate assessment of risk will have to come from prospective
cohort studies. A second weakness in our analytic strategy is
that the rMS analyses in ﬁve of the genes included here—ATM,
BARD1, MRE11A, RAD50 and NBN—are somewhat dependent
on our deﬁnitions of key protein functional domains. This
Table 3 OR estimates and p-values for case–control screening of 18 Breast Cancer Association Consortium SNPs
Control % Case % Adjusted OR CI* p>|z|
Utilizing NPS as a continuous score
All 1057 100 1236 100 5.76×10−10
Only Caucasians 904 85.5 788 63.8 3.47×10−10
Excluding Caucasian 153 14.5 448 36.3 0.32
Number of subjects at risk indicated by NPS score above Threshold group
All† 13 1.2 26 2.1 2.56 1.26 to 5.19 0.009
Only Caucasian† 12 1.3 25 3.2 3.02 1.45 to 6.29 0.003
Excluding Caucasian Never ≥2.5
OR of top and bottom percentiles using middle quintile as reference
All
0–1% 11 1.0 5 0.4 0.50 0.16 to 1.56 0.232
1–5% 42 4.0 28 2.3 0.72 0.42 to 1.24 0.239
95–99% 41 3.9 73 5.9 1.99 1.27 to 3.12 0.003
99–100% 11 1.0 22 1.8 2.74 1.27 to 5.90 0.010
Only Caucasian
0–1% 10 1.1 3 0.4 0.48 0.13 to 1.81 0.278
1–5% 36 4.0 19 2.4 0.80 0.44 to 1.48 0.482
95–99% 36 4.0 51 6.5 2.00 1.22 to 3.26 0.006
99–100% 10 1.1 22 2.8 3.20 1.45 to 7.08 0.004
*Adjusted for study centre and race/ethnicity.
†NPS≥2.1. NPS, normalised polygene score.
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analytic element is in need of independent evaluation and
reﬁnement.
Our analysis raises additional questions regarding standard
clinical genetic testing practices using panel tests. For the estab-
lished moderate-risk genes ATM, CHEK2 and NBN, the major-
ity of the pathogenic variants that the test can actually detect
are rMS, likely to be reported to patients as VUS, and likely to
be normalised during counselling. In this circumstance, how
does one answer the clinical validity question, “Are the variants
the test is intended to identify associated with disease risk, and
are these risks well quantiﬁed?”41 What is the impact on
studies intended to explore the penetrance and tumour spec-
trum of pathogenic variants in these genes if the studies focus
on T+SJVs even though these may represent a minority of the
pathogenic variants? One path forward lies in a more nuanced
use of the IARC 5-class system for variant classiﬁcation and
reporting to incorporate more data from ongoing research on
missense substitution evaluation.49 From work that deﬁned the
sequence analysis-based prior probabilities of pathogenicity for
rMS in BRCA1, BRCA2 and the mismatch repair genes, one can
clearly deﬁne subsets of rMS that have relatively high probabil-
ities of pathogenicity.2 42 A straightforward approach for clini-
cians could be to make systematic efforts to enrol carriers of
high probability of pathogenicity rMS in research studies, such
as those coordinated through the Evidence-based Network for
the Interpretation of Germline Mutant Alleles (ENIGMA) con-
sortium,50 while still describing these ﬁndings to patients as
VUS. For BRCA1, BRCA2 and the mismatch repair genes, these
could be deﬁned as rMS with prior probabilities of pathogenicity
of ≥0.66 as deﬁned at the calibrated prior probability of patho-
genicity websites (priors.hci.utah.edu/PRIORS/index.php and
hci-lovd.hci.utah.edu/home.php, respectively). rMS from the
nine genes examined here that are placed in an OR≥2.5 group-
ing by two or more of the missense analysis programs similarly
fall into a relatively high probability of pathogenicity subset.
VUS with lower probabilities of pathogenicity could reasonably
be normalised since future reclassiﬁcation to a clearly pathogenic
variant is rather unlikely. Such an approach would better priori-
tise those missense substitutions with high probabilities of patho-
genicity, leading to better understanding of these VUS by
clinicians and patients. This approach should empower research
towards gene validation, penetrance and tumour spectrum and
thereby address the question of clinical validity in the future.
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PANCREATIC CANCER AS AN INCLUSION FACTOR FOR 
GENETIC TESTING OF BREAST AND COLORECTAL 
CANCER SUSCEPTIBILITY GENES 
Abstract 
Genes associated with hereditary breast and ovarian cancer (HBOC) and 
colorectal cancer (CRC) susceptibility have been shown to play a role in pancreatic  
cancer susceptibility. Germline genetic testing of pancreatic cancer cases could be  
beneficial for at-risk relatives with pathogenic variants in established HBOC and CRC  
genes, but it is unclear how many pancreatic cancer cases harbor pathogenic variants in  
those genes. 55 breast, 25 ovarian, and 66 pancreatic cancer cases diagnosed at the  
Huntsman Cancer Hospital, SLC, UT, unselected for family history were sequenced on a  
custom 34 gene panel including known HBOC and CRC genes. Variants of uncertain  
significance were down-weighted based on prior probabilities from public databases if  
available or predictions of deleteriousness from in silico predictors. A second set of 95  
unselected pancreatic cancer cases, the pancreatic cancer cases of the Cancer Genome  
Atlas, and an unselected pancreatic cancer screen from the Mayo clinic were combined in 
a meta-analysis to estimate the proportion of carriers with pathogenic variants. In the 
pancreatic cancer cases, 7.6-8.5% carried a variant that would alter the screening 
recommendations for at-risk relatives, including VUS from known HBOC and CRC  
susceptibility genes. A meta-analysis reveals that approximately 11.9% of unselected  
pancreatic cancer cases carry a pathogenic variant in HBOC or CRC susceptibility genes.  
With the inclusion of both HBOC and CRC susceptibility genes in a panel test, pancreatic 
cancer cases unselected for age or family history have a high enough percentage of  
carriers to rationalize genetic testing for identification of variants that could be further  
used in cascade testing of healthy relatives for increased HBOC and CRC surveillance  
measures. 
Introduction 
Over the last few years, massively parallel sequencing converged with targeted  
capture using array synthesized baits to enable panel testing of most known cancer  
susceptibility genes.1–4 These panel tests then replaced Sanger sequencing of limited sets 
of syndromic genes, revolutionizing the genetic testing landscape. Before panel testing,  
the personal and family history of a cancer patient had to be examined carefully to select 
the most likely syndromic genes. Due to atypical personal or family history combined  
with the nondiscreet nature of cancer susceptibility, there were probably many instances  
where a patient never received the correct test.5–10  
The transition to multigene panel testing brings with it a greater burden of  
Variants of Uncertain Significance (VUS) than syndromic gene testing.5,7,11–14 Most panel 
testing based studies of the proportion of patients with an identifiable genetic  
predisposition focus on clearly pathogenic variants; this analytic strategy results in clarity  
but underestimates the proportion of cases with genetic predisposition. Since 2008, we  
have invested in calibrating computational analyses of missense substitutions and splice  
26
junction variants.15–21 These calibration studies simultaneously validate the utility of the  
computational tools examined, and convert the native output of those tools into a  
Bayesian prior probability of pathogenicity (Prior_P).20,21 In the context of VUS  
classification efforts, this Prior_P is a starting point for clinical classification of VUS.  
Moreover, the Prior_Ps enable probabilistic estimation of the proportion of patients with 
a pathogenic variant detected through panel testing. 
Today, some cancer diagnoses by themselves imply a high enough probability to  
carry a pathogenic variant across a panel of susceptibility genes that panel-based  
predisposition testing is considered automatically appropriate, such as Ovarian Cancer  
(OC) and triple negative Breast Cancer (BC) diagnosed at less than 60 years of age.22–24  
Universal testing of Colorectal Cancer (CRC) tumors for mismatch repair deficiency,  
which is, in effect, a prescreen for Lynch Syndrome (LS), provides a third example.25,26  
Other cancers still require further analysis; for example, the personal and family history  
of patients with luminal BC remains an important determinant for whether they would be 
offered genetic testing. 
Genetic testing of patients with pancreatic cancer (PC) is not yet routine, in part 
because methods for early detection of PC have limited utility.27–30 One substantial  
benefit of genetic testing is application of preventive measures for carriers of disease  
susceptibility alleles, notably the at-risk relatives of probands. PC patients have been  
reported to carry pathogenic variants in a variety of cancer susceptibility genes, notably 
Hereditary Breast and Ovarian Cancer (HBOC) and CRC genes.22,31–39 Indeed,  
systematically testing PC cases for pathogenic germline variants in HBOC and CRC  
genes in order to identify at-risk relatives who would benefit from preventive measures  
for BC, OC, and CRC would be a medically useful application of panel testing. Testing 
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all PC cases, however, is only beneficial if the proportion of carriers among PC cases is  
high enough to justify that testing. To estimate the percentage of PC cases that carry  
variants with potential medical management impact for at-risk relatives, we applied panel 
testing to independent discovery (n = 66) and replication (n = 96) sets of PC patients,  
both unselected for family cancer history. To demonstrate the overlap with HBOC and  
CRC predisposition genes, we tested unselected BC and OC cases, and familial CRC  
cases, in parallel with the discovery set of PC cases. To demonstrate generalizability of  
the results in PC cases, we performed a meta-analysis including published panel tests of  
unselected PC cases. 
Methods 
Subjects and ethics statement 
This study was approved by the Institutional Review Board of the University of  
Utah. All participants gave written consent which included DNA sampling for molecular 
studies and access to medical records.  
Breast (n = 55), ovarian (n = 25) and pancreatic cancer (n = 66) cases were  
selected on the minimal requirements of personal history of cancer and having at least  
two grandparents in the Utah Population Database (UPDB). The individual family  
members are then linked to statewide cancer, demographic, and medical information.40 
BC cases were also selected to equally represent the molecular subtypes including  
luminal (n=20), HER2+ (n=15), and triple negative (n=13) subtypes. Ages at diagnosis 
and family cancer history were obtained after sequencing and variant evaluation. A  
second set of pancreatic cancer cases (n=96) were selected on the basis of being newly  
diagnosed pancreatic cancer cases at the Huntsman Cancer Hospital (HCH), Salt Lake 
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City, UT during the 2014 and 2015 fiscal years. 
UPDB resources were used to identify 51 pedigrees spanning 3-5 generations  
with a statistical excess of CRCs segregating in an autosomal dominant fashion. A pair of 
relatives diagnosed with CRC, both with a first degree relative with CRC (n = 98) was  
selected from each pedigree. The members of these “cousin pairs” were separated by 3 to  
7 meoises.41 
Next-generation sequencing library preparation and custom 
targeted capture 
Blood-derived genomic Deoxyribonucleic acid (DNA) (100ng - 1µg) was sheared 
using a Covaris S2 instrument (Covaris, Woburn, MA, United States). For BC, OC, and  
PC cases, libraries were prepared using the Ovation Ultralow Library System (NUGEN # 
0329). For DNA from OC cases extracted from grossly uninvolved tissue from FFPE  
blocks (n = 11), 2 µl of Uracil-DNA Glycosylase (UDG) (NEB #M0280S) were added to 
samples following adapter ligation and incubated for 37°C for 15 min, prior to ligation  
clean-up in order to reduce C>T artifacts.42 For the CRC cases, libraries were prepared  
using the NEBNext DNA Library Prep Reagent Set for Illumina (NEB # E6000)  
according to the manufacturer’s instructions.  
Library enrichment for a 34 or 59 gene custom panel was done with the Roche 
SeqCap EZ Choice Library (cat# 06266339001) and the SeqCap EZ Reagent Kit Plus v2  
(NimbleGen #06-953-247-001) using the manufacturer’s protocol. Individual libraries  
were combined into pools of 6-12 prior to hybridization. Captured libraries were  
sequenced on a Illumina HiSeq2000 channel using the HiSeq 101 Cycle Paired-End  
sequencing protocol. A complete list of genes captured is included in Supplemental Table 
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S3.1. 
Sequences from the Utah cohort with ≥ 100X coverage as determined by  
CoverageBED,43 as well as 154 PC cases from the Cancer Genome Atlas (TCGA) were 
analyzed using the USeq (useq.sourceforge.net) in-house pipeline, according to the  
Genome Analysis Toolkit (GATK v.3.3-0) best practices recommendations.44 Variants  
with a mapping quality score less than 20 were excluded. ANNOVAR was used for  
variant functional annotation followed by conversion to Human Genome Variation  
Society (HGVS) nomenclature using Mutalyzer.45,46 
Sequence variant evaluation 
Truncating variants not present in the final exon of a gene were considered  
pathogenic. The following filters were used to exclude variants from further analysis:  
minor allele frequency  0.1% in one or more populations from the Exome Aggregation 
Consortium (ExAC) database (exac.broadinstitute.org); synonymous/intronic variants  
with no predicted effect on splicing via MaxEntScan;47 variants reported as probable- 
nonpathogenic/nonpathogenic by more than one source with no conflicting reports in  
ClinVar (www.ncbi.nlm.nih.gov/clinvar).  
Variants of uncertain significance (VUS) were included if their estimated  
probabilities of pathogenicity were >0.8 based on in silico predictions from publically  
available databases for the MMR genes (hci-lovd.hci.utah.edu), or BRCA1/2  
(http://priors.hci.utah.edu/PRIORS/). VUS of this type were weighted according to their 
Prior_P score. The remaining rare VUS were included if two of the following criterion  
were met using in silico predictions: C35+ from Align-GVGD, MAPP score ≥11,  
Polyphen-2 HUMVAR score ≥0.9, and a CADD PHRED score ≥23.48–52 Weights were  
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loosely based off of the likelihood ratios identified for BRCA1/2,21 with a weight of 0.66  
 
being used for a minimal overlap of two programs, and 0.81 for an overlap of three or  
 
more. Canonical splice acceptor/donor variants predicted to impact splicing were given  
 
the weight of 0.97 if the effect of the variant had not been demonstrated experimentally.  
 
Known and likely pathogenic sequence variants were confirmed via Sanger sequencing.53  
 
VUS in published studies used for meta-analysis were graded with the same weights and  
 
severity, although were not confirmed via Sanger sequencing. An overview of the  
 






STATA V.12.1 (StataCorp, College Station, Texas, USA) was used to conduct  
 
meta-analyses and calculate BC/OV/PC cohort carrier percentage 95% confidence  
 
intervals. The meta-analyses to compare the carrier frequencies between the different PC  
 
cohorts were conducted using metaprop under a random effects model, using Freeman- 
 
Tukey transformation to stabilize the variances over the studies.54 The R package ggplot2  
 
was used to plot the meta-analyses. Other PC case screens were identified on the basis of  
 
being recent (2014+), and including BRCA1/2 variants. VUS were weighted as described  
 
when possible. The observed incidence of variants in the unselected PC cases, and other  
 
published studies (see Figure 3.1) were compared with the expected incidence of variants  
 
in non-TCGA ExAC controls (excluding the Finnish and undescribed populations) as a  
 
Standardized Incidence Ratio (SIR).55 Significance tests and confidence intervals were  
 
estimated based on a Poisson distribution.56 For the meta-analysis and SIR calculation,  
 
the genes were split into subgroups of high- and moderate-risk cancer susceptibility  
 
genes. High- and moderate-risk were definted as genes with a cumulative risk at age  
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Targeted multigene panel of 34 genes 
 
Multigene panel testing with our custom 34-gene panel was conducted in 237  
 
individuals (Table 3.1). We identified 15 truncating variants in 18 individuals (Table 3.2).  
 
The remaining 183 missense substitutions underwent further in silico analysis. Five VUS  
 
in BRCA1/2 and the MMR genes were considered to have an elevated probability of  
 
pathogenicity (prior probability ≥0.8). A large portion of the risk attributable to  
 
moderate-risk genes is due to missense substitutions,51 which are generally classified as  
 
VUS. To estimate the number of carriers of pathogenic missense variants, subjects with  
 
relatively high probability of pathogenicity VUS were weighted according to the  
 




Breast and ovarian cancer cases, unselected for family history 
 
BC cases were ascertained with three different subtypes: luminal, HER2+, and  
 
triple negative. The Genetic Counselors at HCH were very active towards BC cases,  
 
which would have removed most cases with a personal or family history qualifying them  
 
for clinical testing from our pool of candidates. Nonetheless, two luminal BC cases  
 
carried pathogenic BRCA2 variants. No pathogenic or potentially pathogenic variants  
 
were found in HER2+ BC. One triple negative BC case carried a variant of interest. After  
 
weighting carriers for the VUS, 10% of luminal and 7.7% of triple negative BC cases  
 
carried a potentially pathogenic variant (Table 3.2).  
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OC has been associated with BC genes, as well as LS genes.57 As such, it was not  
 
surprising to identify pathogenic variants in the BC genes BRCA1, BRCA2, and RAD50,  
 
and two VUS in the LS genes MSH2 and MSH6 in the OC cases. Combining the  
 
proportion of carriers of pathogenic and VUS suggest 23.6% of OC cases carry a  
 
potentially medically actionable variant (Table 3.2), a much higher carrier percentage  
 




Colorectal cancer cases, selected for moderate family history 
 
Five pathogenic variants were identified in seven CRC cases from five families  
 
(Table 3.2). These included two MSH2 truncating variants: one found in both members of  
 
the relative pair, and the other segregating in just one branch of the pedigree. A large  
 
deletion encompassing part of EPCAM and MSH2 exons 1-8 was shared by another  
 
cousin pair which met Amsterdam II criteria for LS testing, but this was not confirmed by  
 
other sequencing means. A BRCA2 frameshift variant, c.6275_6276del, was identified in  
 
one individual with multiple instances of early onset BC, including a daughter diagnosed  
 
at 36 years of age. There were also two VUS of interest (Table 3.2). The VUS BRCA2  
 
p.(W31C) was only carried by one case of the target pair. The carrier was diagnosed with  
 
OC and CRC, while the noncarrier was diagnosed with BC, endometrial cancer, and  
 
CRC. There were no other instances of BC or OC recorded in the family.  
 
It is important to note that three out of the seven of variants identified in the CRC  
 
cases were in HBOC genes. Although the large proportion of HBOC variants identified is  
 
partially attributed to prescreening many of these families for MMR variants, this is an  
 
example where multigene panel testing offers a greater benefit beyond sequencing  
 
limited to CRC risk genes.  
33
Pancreatic cancer cases, unselected for family history 
In the initial 66 pancreatic cancer cases, 4 pathogenic variants were identified in  
BRCA2, MSH6, PALB2, and STK11; and 2 VUS in ATM. After weighting, 8.5% of PC  
cases carry a variant with potential medical management impact for relatives (Table 3.2). 
To replicate this observation, 95 independent PC cases underwent a multigene panel test, 
updated since the initial panel test to include genes associated with hereditary  
predisposition to cancer. In the second set of PC cases, three pathogenic variants and six  
VUS were identified (Table 3.3). In addition to in silico predictions, CHEK2 p.(T476M)  
was found to be damaging in a functional assay for CHEK2 variants 58, and was thus  
weighted more strongly towards being pathogenic. After weighting carriers, we found  
7.8% of the replication series of PC cases, unselected for family history carried a variant  
with potential medical impact.  
APC p.R99W 
Three unrelated PC and one CRC case carried APC c.295C>T p.(R99W).  
Although earlier studies describe this variant as possibly pathogenic,59 missense  
substitutions in APC are rarely associated with disease, and a more recent study  
concluded that this variant is benign.60,61 Colonoscopy at the age of 64 on two of these  
individuals did not find evidence of adenomatous polyposis, suggesting further that this 
variant is benign.  
Carrier frequencies across studies 
Our two sets of pancreatic cancer cases were combined with a published study of 
unselected PC cases from the Mayo Clinic (n = 96),62 plus the PC cases from TCGA  
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(n=154), in a meta-analysis (Figure 3.2). Further, the gene burdens observed in the Utah,  
 
Mayo, TCGA, and other recently published PC genetic screening studies were compared  
 
to the non-TCGA ExAC (n=49,451) as a population sample (Table 3.4; Supplemental  
 
Table S3.3).4,31,33,34,55,63–65 Among unselected PC cases, 2.9% (1.4-4.8%) carried a  
 
pathogenic variant in a high-risk HBOC susceptibility gene (BRCA1/2 or PALB2; SIR 7.7  
 
[6.5-9.0], p<0.0001). PC is part of the LS spectrum,66 thus it was not surprising that 1.4%  
 
(0.3-3.0%) of unselected PC cases were carriers (SIR 2.4 [1.5-3.6], p = 6.8x10-04). For the  
 
moderate-risk homologous recombination repair (HRR) BC genes ATM, NBN, and  
 
CHEK2, 5.0% (2.1-8.8%) of unselected PC cases were estimated to carry a pathogenic  
 
variant (SIR 2.5 [1.8-3.2], p<0.0001). Combining these genes with others included in this  
 
study, such as MRE11A, RAD50, etc., 11.9% (8.2-16.2%) of unselected PC cases carry a  
 
variant that could impact the medical management of carriers' relatives (SIR 3.30 [2.95- 
 
3.68], p<0.0001). Although, not included in the meta-analysis or further analyses there  
 






Through systematic panel testing of PC cases unselected for family history, we  
 
estimate that 1.4% of probands carry a pathogenic allele of a LS gene (MLH1, MSH2,  
 
PMS2, or MSH6), 2.9% carry a pathogenic allele of a high-risk HBOC gene (BRCA1,  
 
BRCA2, or PALB2), and an additional 5% carry a pathogenic allele of a moderate-risk  
 
homologous recombination repair pathway breast cancer gene (i.e., ATM, CHEK2, or  
 
NBN). Among PC cases, for each of these three groups of genes, the burden of  
 
pathogenic alleles is significantly higher than in the population sample represented by  
 
non-TCGA ExAC, supporting an argument that these are not incidental findings. Adding  
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other high-risk genes such as TP53, CDKN2A, and STK11 to the mix results in >10% of  
 
PC cases with a sequence variant that would alter medical management of healthy at-risk  
 
relatives. Focusing on individual genes, the top five genes with potential medical impact  
 
for at-risk relatives were BRCA2, ATM, BRCA1, CDKN2A, and CHEK2. Here we note  
 
that ATM and CHEK2 have recently been added to NCCN’s list of genes with associated  
 
medical actionability for BC.22 
 
Turning to CRC, pathogenic variants in BRCA2 and CHEK2 were observed in  
 
target cousin pairs with unexplained CRC. While it is no longer a surprise that multigene  
 
panel testing identifies variants in genes that do not match the sentinel cancer, the more  
 
important point is that from the perspective of potential cancer prevention in at-risk  
 




Today, universal LS testing, beginning with an immunohistochemical (IHC) or  
 
microsatellite instability (MSI)-based prescreen of tumors followed by germline testing  
 
for indicated individuals, is already recommended for newly diagnosed CRC cases. For  
 
perspective on this universal testing guideline, Erten et al. recently reported from a  
 
pooled analysis that prescreen based universal testing finds pathogenic LS variants in  
 
about 1.2% of all CRC cases, whereas direct sequencing based universal testing finds  
 
pathogenic LS variants in about 2.5% of CRC cases.68–75 The differences in detection rate  
 
between the two strategies was attributed largely to loss to follow-up. A health economics  
 
analysis within Erten et al also concluded that when the cost of sequencing the mismatch  
 
repair genes drops below $609, universal testing based on sequencing alone will become  
 
more cost effective than universal testing that cascades through IHC or MSI, echoing a  
 
similar finding by Gould-Suarez et al.75,76  
36
Based on our results, universal testing of PC patients using a panel test would  
 
identify pathogenic LS variants in about same proportion of cases as does prescreen  
 
based universal testing of CRC patients. Moreover, the panel test’s ability to identify  
 
pathogenic variants in the high-risk HBOC genes plus susceptibility genes such as TP53,  
 
CDKN2A, and STK11, results in a proportion of PC patients with a high-risk variant that  
 
is notably higher than direct sequencing for LS (alone) finds in CRC patients. Since two  
 
companies, Color Genomics and Invitae, already offer panel tests at less than $609, there  
 
are really two factors that stand in the way of adopting universal testing for PC patients:  
 
(1) systematic illogic in insurance coverage determinations, (2) inefficiency in  
 
classification of VUS in high-risk susceptibility genes.  
 
For several of these high-risk susceptibility genes, solutions to the VUS problem  
 
are almost in hand. Calibrated sequence analysis-based prior probability of pathogenicity  
 
models already exist for the four LS genes, BRCA1, and BRCA2,18,19 and there is no  
 
obvious barrier to extending these models to TP53. High quality functional assays also  
 
exist for missense substitutions in these seven genes.77–82 Therefore, universal panel  
 
testing of PC patients followed by collation of the obviously pathogenic variants,  
 
systematic application of the Bayesian Integrated Evaluation to the high probability of  
 
pathogenicity VUS found through the testing,83–86 and cascade testing of at-risk relatives  
 
has the potential to add years to the lives of these at-risk relatives in much the same way  
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 Figure 3.2. Forest plots of the proportion of carriers in pancreatic cancer screens. A meta-
analysis between the unselected PC cases from HCH, the Mayo Clinic, and the PC cases 
of The Cancer Genome Atlas (TCGA). A list of genes for each analysis is found in 
Supplemental Table 1. HBOC = Hereditary Breast and Ovarian Cancer; HRR = 
Homologous Recombination and Repair; ICR = Interstrand Crosslink Repair; OC = 
Ovarian Cancer; BC = Breast Cancer 
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 Table 3.1: Demographics for 34 and 59 gene screen 
 Total % Female Average Age of Onset (low-
high) 
Breast Cancer Cases 48 100 51.9 (28-84) 
Luminal 20 100 51.5 (30-84) 
HER2+ 15 100 51.5 (30-77) 
Triple Negative 13 100 53.3 (28-78) 
Ovarian Cancer Cases 25 100 55.1 (34-82) 
Pancreatic Cancer Cases (First Set) 66 47.0 66.6 (43-91) 
Pancreatic Cancer Cases (Second Set) 95 44.8 66.0 (43-86) 
Colorectal Cancer Cases 98 47.0 64.8 (28-94) 
 
49
Table 3.2: Pathogenic variants and variants of high probability of pathogenicity identified 
from a custom 34-gene panel for breast cancer, ovarian cancer, colorectal cancer, and 
pancreatic cancer cases 
Gene HGVS Sex: Age of Onset (Subtype) Weight 
Breast Cancer Cases 
BRCA1 c.856_857del p.(S286*) F: 41 (Triple Negative) 1a 
BRCA2 c.1189_1190insTTAG
p.(Q397Lfs*25)
F: 30 (Luminal) 1 
BRCA2 c.1832C>A p.(S611*) F: 37 (Luminal) 1 
MRE11A c.564G>C p.(R188S) F: 41 (Triple Negative) -a
Carrier Frequency: 
 Luminal 2/20=10% (1.23-31.70%) 
 HER2+ 0/15=0% 
 Triple Negative 1/13=7.69% (0.19-36.03%) 
Ovarian Cancer Cases 
BRCA1 c.3066del p.(V1023*) F: 59 1 
BRCA2 c.6275_6276del
p.(L2092Pfs*7)
F: 58 1 
MSH2 c.2260A>G p.(T754A) F: 53 0.96 
MSH6 c.3674C>T p.(V1253E) F: 41 0.94 
RAD50 c.1958C>A p.(S653*) F: 46 1 
RAD51C c.577C>T p.(R193*) F: 55 1 
Carrier Frequency: 5.90/25=23.6% (9.36-45.13%) 
Colorectal Cancer Cases 
BRCA2 c.93G>T p.(W31C) F: 61 0.81 
BRCA2  c.6275_6276del
p.(L2092Pfs*7) 
F: 59 1 
CHEK2 c.1100del p.(T367Mfs*15) M: 49 1 




MSH2 c.592G>T p.(E198*) F: 63 1 
MSH2 c.1375G>C p.(D459H) M: 67 0.87 




Number of Identified Variants with Possible BC Recommendations: 3/7=42.9% 
Pancreatic Cancer Cases 
ATM c.7327C>G p.(R2443G) M: 66 0.81 
ATM c.8734A>G p.(R2912G) F: 65 0.81 
BRCA2  c.3873del p.(Q1291Hfs*2) M: 54 1 
MSH6 c.3261dup p.(F1088Lfs*5) F: 57 1 
PALB2 c.1240C>T p.(R414*) F: 69 1 
STK11 c.738C>A p.(Y246*) M: 45 1 
Carrier Frequency: 5.62/66=8.52% (3.41-18.7%) 
a The same individual carried both variants, so carrier weight was combined and only counted 
once. bNot confirmed via secondary means 
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 Table 3.3: Pathogenic variants and variants with high probability of pathogenicity 
identified in a second set of 95 pancreatic cancer cases, unselected for family history 
Gene HGVS Sex: Age of Onset Carrier 
ATM c.8734A>G p.(R2912G) M: 74 0.81 
BRCA1 c.68_69del p.(E23Vfs*17) M: 74 1 
BRCA2 c.3974_3975insTGCT p.(T1325Cfs*4) M: 71 1 
CHEK2 c.1159A>G p.(T387A) M: 81 0.81 
CHEK2 c.1427C>T p.(T476M) F: 50 0.99a 
MRE11A c.923dupT p.(M309Hfs*8) M: 56 1 
MSH6 c.3851C>T p.(T1284M) F: 68 0.94 
RAD50 c.3641G>A p.(R1214H) F: 50 -a 
TP53 c.847C>T p.(R283C) M: 65 0.81 
 Carrier Frequency: 7.36/95=7.75% (3.01-14.6%) 








































































































































































































































































































































































































































































































































































































































































































































Supplemental Table S3.1. List of genes for custom 34 and 59 gene capture and inclusion 




























































































































































APC Y Y Ya Ya Ya Ya 
ATM Y Y Yc Yc Yc 
AXIN2 Y Y 
BAP1 Y 
BARD1 Y Y Yd Yd 
BMPR1A Y Y Ya Ya Ya Ya 
BRCA1 Y Y Y Y Y Y 
BRCA2 Y Y Y Y Y Y 
BRIP1 Y Y Ya Ya Ya 
CDH1 Y Y Ya Ya 
CDK4 Y 
CDKN2A Y Y Ya Ya Ya Ya 
CHEK2 Y Y Yb Yb Yb 
CTNNB1 Y Y 
DICER1 Y 
FLCN Y Y 
MAX Y 
MEN1 Y 
MLH1 Y Y Y Y Y Y 
MLH3 Y Y 
MRE11A Y Y Ye Ye 
MSH2 Y Y Y Y Y Y 
MSH6 Y Y Y Y Y Y 
MUTYH Y Y 
NBN Y Y Yg Yg Yg 
NF1 Y Y Y 
PALB2 Y Y Ya Ya Ya Ya 
PHOX2B Y 
PKHD1 Y 
PMS1 Y Y 






PTEN Y Y Ya Ya Ya Ya 
RAD50 Y Y Yf Yf 
RAD51B Y Y 
RAD51C Y Y Y Y Y 



































































































































































SMAD4 Ya Ya Ya Ya 
STK11 Y Y Ya Ya Ya Ya 
SUFU Y 
TCF7L2 Y Y 
TGFBR2 Y Y 
TMEM127 Y 
TP53 Y Y Y Y Y Y 
VHL Y 
WT1 Y 
XRCC2 Y Y 
XRCC3 Y Y 
a Only clearly deleterious truncating and splice junction variants as well as known pathogenic missense 
were included; b CHEK2 exons 13-16 and PMS2 exons 1-5, 9, and 11-15 were excluded due to possible 
pseudo-gene contamination in ExAC1; c Only missense substitutions position 1960+ were included2; d Only 
missense substitutions in the RING, BRCA1 interaction, and BRCT domains were included3; e Only 
missense substitutions in the Phosphoesterase, RAD50 interaction, and GAR domains were included4; f 
Only missense substitutions in the ATPase, MRE11A interaction, and Zinc hook domains were included4; g 
Only missense substitutions in the GHA, BRCT, and MRE11A domains were included4. HBOC = 
Hereditary Breast and Ovarian Cancer; HRR = Homologous Recombination and Repair; BC = Breast 
cancer; ICR = Interstrand Crosslink Repair; OC= Ovarian Cancer. 
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 Supplemental Table S3.2. List of rare variants with corresponding information used to 
identify potentially pathogenic variants and weights for patients screened from the 
Huntsman Cancer Hospital 
Gene Accession DNA Change Protein Change Type ExAC freq Prior A M C P W 
ATM NM_000051 c.6067G>A  p.(G2023R) MS 0.0016 NA C65 45.39 30 0.999 0 
ATM NM_000051 c.7327C>G p.(R2443G) MS 8.334X10-6 NA C65 25.9 17.45 0.984 0.81 
ATM NM_000051 c.8734A>G  p.(R2912G) MS 0.0002883 NA C65 25.9 20.7 1 0.81 
BARD1 NM_000465 c.2216A>G  p.(K706E) MS 5.65E-05 NA C0 16.22 16.9 0.265 0 
BMPR1A NM_004329 c.1385C>T p.(P462L) MS 0 NA C65 26.92 28.4 1 0 
BRCA1 NM_007294 c.68_69del  p.(E23Vfs*17) FS 0.0002 -  - -  - -  1 
BRCA1 NM_007294 c.856_857del  p.(S286*) FS 0 - - - - - 1 
BRCA1 NM_007294 c.3066del p.(V1023*) FS 0 - - - - - 1 
BRCA1 NM_007294 c.3708T>G p.(N1236K) MS 0.0002389 0.02 C0 - - 0.011 0 
BRCA1 NM_007294 c.4165_4166del p.(S1389*) FS 1.059X10-5 - - - - - 1 
BRCA2 NM_000059 c.93G>T p.(W31C) MS 0 0.81 C65 - 20.7 1 0.81 
BRCA2 NM_000059 c.1189_1190insT
TAG 
p.(Q397Lfs*25) FS 0 - - - - - 1 
BRCA2 NM_000059 c.1832C>A p.(S611*) SG 0 - - - 38 - 1 
BRCA2 NM_000059 c.3873del p.(Q1291Hfs*2) FS 0 - - - - - 1 
BRCA2 NM_000059 c.3975_3978dup  p.(A1327Cfs*4) FS 9.678X10-6 -  - -   - -  1 
BRCA2 NM_000059 c.6275_6276del p.(L2092Pfs*7) FS 0 - - - - - 1 
CHEK2 NM_001005735 c.1100del p.(T367Mfs*15) FS 0.001818 NA - -  - 1 
CHEK2 NM_001005735 c.1159A>G  p.(T387A) MS 0 NA C65 24.17 26.6 0.973 0.81 
CHEK2 NM_001005735 c.1427C>T  p.(T476M) MS 0.0004 NA C65 23.02 19.54 0.997 0.95b 
DICER1 NM_177438 c.5623G>A  p.(D1875N) MS 0 NA C15 13.97 33 0.176 0.66 
EPCAM  EPCAM:ex1-9_MSH2:ex1-8 D - - - - - - 1 
MLH1  NM_000249 c.1136A>G p.(Y379C) MS 3.77E-05 0.46 C15 - 16.5 0.966 0 
MLH3 NM_014381 c.2221G>T  p.(V741F) MS 0.015 NA - - 6.398 0.518 0 
MLH3 NM_014381 c.3539G>A  p.(R1180H) MS 0.0001 NA C25 32 14.41 0.999 0 
MLH3 NM_014381 c.716T>G p.(I239S) MS 0.0001 NA C65 20.83 17.29 0.984 0 
MRE11A NM_005591 c.564G>C  p.(R188S) MS 0 NA C65 21.57 17.31 1 0.81 
MRE11A NM_005591 c.826C>T  p.(P276S) MS 0 NA C0 6.04 26.8 0.856 0 
MRE11A NM_005591 c.923dup p.(M309Hfs*8) FS 0 NA  - -    -  1 
MSH2 NM_000251 c.138C>G p.(H46Q) MS 1.89E-04 0.74 C15 14.29 26.7 1 0 
MSH2 NM_000251 c.260C>G p.(S87C) MS 0.0003076 0.79 C15 20.41 15.8 0.961 0 
MSH2 NM_000251 c.592G>T p.(E198*) SG 0 - - - 24.3 - 1 
MSH2 NM_000251 c.815C>T p.(A272V) MS 2.17E-04 0.40 C0 19.40 32 0.944 0 
MSH2 NM_000251 c.1375G>C p.(D459H) MS 0 0.87 C65 20.32 21.8 0.977 0.87 
MSH2 NM_000251 c.2260A>G p.(T754A) MS 0.0000165 0.96 C65 37.99 24.7 0.991 0.96 
MSH2 NM_000251 c.2662del p.(L888Cfs*4) FS 0 - - - - - 1 
MSH6 NM_000179 c.3261dup p.(F1088Lfs*5) FS 0.001753 - - - - - 1 
MSH6 NM_000179 c.3674C>T p.(T1225M) MS 0.0001156 0.73 C65 29.50 28.7 0.99 0 
MSH6 NM_000179 c.3758T>A p.(V1253E) MS 0.0001897 0.94 C65 32.45 29.4 0.99 0.94 
MSH6 NM_000179 c.3851C>T p.(T1284M) MS 0.0002 0.94 C65 29.50 18.23 0.999 0.94 
NBN NM_001024688 c.283G>A p.(D95N) MS 0.0019 NA C0 13.92 18.24 1 0 
PALB2 NM_024675 c.1240C>T p.(R414*) SG 0 NA - - 38 - 1 
PMS2 NM_000535 c.86G>C p.(G29A) MS 0.0004763 0.89 C55 22.05 32 0.999 0c 
PMS2 NM_000535 c.953A>G p.(Y318C) MS 0.0003567 0.72 C55 14.49 16.74 0.981 0 
PMS2  NM_000535 c.1004A>G p.(N335S) MS 2.45E-04 0.61 C45 13.40 23.3 0.996 0 
PMS2 NM_000535 c.1490G>A  p.(G497D) MS 7.53E-05 0.001 C0 3.02 10.16 0.382 0 
POT1 NR_003102 c.1810G>A p.(E604K) MS 0 NA C55 19.98 26.5 0.907 0.81 
PTEN NM_000314 c.841C>G p.(P281A) MS 0 NA C0 2.41 15.88 0.76 0 
RAD50 NM_005732 c.280A>C p.(I94L) MS 0.003473 NA C0 8.94 15.56 0.003 0 
RAD50  NM_005732 c.980A>G p.(R327H) MS 0.003 NA C0 5.64 27.7 0.742 0 
RAD50 NM_005732 c.1958C>A p.(S653*) SG 4.136X10-5 NA - - 39 - 1 
RAD50 NM_005732 c.3641G>A p.(R1214H) MS 0 NA C25 14.41 36 1 0.81 
RAD51B NM_002877 c.728A>G p.(K243R) MS 0.007347 NA C25 - 25.4 1 0 
RAD51C NM_058216 c.577C>T p.(R193*) SG 4.136X10-5 NA - - 22 - 1 
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Supplemental Table S3.2. continued 
Gene Accession DNA Change Protein Change Type ExAC freq Prior A M C P W 
TGFBR2 NM_001024847 c.1234G>A p.(V412M) MS 0.001156 NA - - 17.28 0.954 0 
TP53 NM_000546 c.847C>T p.(R283C) MS 0.0001 NA C55 26.18 13.04 0.987 0.81 
XRCC3 NM_005432 c.448C>T p.(R150C) MS 0.0002 NA C65 29.01 17.5 0.997 0.81 
XRCC3 NM_005432 c.617T>G p.(M206R) MS 0 NA C0 32.16 15.77 0.10 0 
a Because of allele frequency observed from sequencing, this variant is believed to be mosaic. bIn silico predictions plus 
the additional information from a functional assay,5 this variant has a higher likelihood of being pathogenic. c Although 
this variant is rare enough and has a prior probability that meets threshold, this variant was identified in homozygous 
state in the ExAC database, which significantly decreases its chances of being pathogenic. d This individual did not 
have any indication of Cowden’s syndrome. PC= Pancreatic Cancer; OC = Ovarian Cancer; BC = Breast Cancer; CRC 
= Colorectal Cancer; MS = Missense; FS = Framshift; SG = Stopgain; D = Deletion; A = Align-GVGD; M = MAPP; C 
= CADD; P = Polyphen-2; W = Weight. 
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Supplemental Table S3.3. List of datasets used for meta-analysis and standardized 
incidence ratio calculations 
Study Sample 
Size 
Selection Criteria Genes Reported 
HCH PC 1 66 Unselected Supplemental Table 1 
HCH PC 2 95 Unselected Supplemental Table 1 
TCGA PC 
Cases 
154 Supplemental Table 1 
Catts 2016 164 Familial PC Families PRSS1, SPINK, STK11, 
CDKN2A, APC, MLH1, 
MSH2, MSH6, PMS2, 
BRCA1, BRCA2 
Holter 2015 306 Unselected BRCA1, BRCA2 
Salo-Mullen 
2015 
159 Unselected BRCA1, BRCA2, PALB2, 
MLH1, MSH2, MSH6, 
PMS2, FAMMM 
Waddell 2015 100 Unselected BRCA1, BRCA2, PALB2, 
ATM, FANCM, XRCC4, 
XRCC6 
Hu 2015 96 Unselected BRCA1, BRCA2, PALB2, 
ATM, BARD1, BRIP1, 
RAD51C, RAD51D, 
CHEK2, MRE11A, NBN, 




Zhen 2014 727 521/727 unrelated probands 
met criteria for familial 
pancreatic cancer 
BRCA1, BRCA2, PALB2, 
CDKN2A 
Grant 2015 290 Family History of Breast 
and/or Ovarian cancer, 
Pancreatic cancer or neither 
APC, ATM, BRCA1, 
BRCA2, CDKN2A, 
MLH1, MSH2, MSH6, 
PALB2, PMS2, PRSS1, 
STK11, TP53 
Roberts 2015 593 Kindreds of Familial 
Pancreatic Cancer 
Whole Genome/87 genes 
Non-TCGA 
ExAC 
49,451 Excluding FIN and OTH 
subgroups 
Supplemental Table 1 
HCH = Huntsman Cancer Hospital, SLC, UT; PC = Pancreatic Cancer; TCGA = The 
Cancer Genome Atlas 
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APPENDIX  
PATHWAY-WIDE PROTEIN MULTIPLE SEQUENCE 
ALIGNMENTS 
Introduction 
In a polygenic model, multiple variants conferring small amounts of susceptibility 
can be combined together to estimate risk.1 In our previously published case-control  
mutation screening studies of ATM, CHEK2, MRE11A, NBN, RAD50, RAD51, RINT1,  
and XRCC2,2–7 we repeatedly found that the summed frequency of bioinformatically  
predicted deleterious missense substitutions exceeded that of protein truncating variants.  
Here, we add BARD1 mutation screening data to the analysis and apply consistent  
analytic models across the rare variants from all nine genes detected in an ethnically  
diverse sample of 1,297 breast cancer cases and 1,121 controls from Chapter 1. Given  
that the nine intermediate-risk genes operate together in the Homologous Recombination  
and Repair (HRR) pathway, we explored the combined evaluation of these genes with a  
concatenated reading frame of 8,611 amino acids. We estimated the scores from the  
missense substitution analysis programs Align-GVGD8 and MAPP9 required to identify a 
group of missense substitutions that reach an average OR ≥2.5.  
We used both Align-GVGD and MAPP8,9 to assign severity scores to the rare  
missense substitutions (rMS). For programs that require a user-generated protein multiple 
sequence alignment (pMSA), it has been suggested that the pMSA for each gene needs to  
 
consist of high quality orthologous sequences with enough variation to average at least  
 
three amino acid substitutions per position from orthologous sequences (3S/P).10–12 This  
 
idea, however, creates paradoxes when applied to highly conserved proteins, such as  
 
RAD51. In an effort to generalize and smooth the idea of 3S/P, we chose twenty genes  
 






Protein multiple sequence alignment organisms 
 
Orthologs from Human (Homo sapiens), either mouse (Mus musculus) or rat  
 
(Rattus norvegicus) from clade Murinae, either pig (Sus scrofa), cow (Bos taurus), dog  
 
(Canis lupus) or panda (Ailuropoda melanoleuca) from clade Laurasiatheria, elephant  
 
(Loxodonta africana), armadillo (Dasypus novemcinctus), either opossum (Monodelphis  
 
domestica) or tasmanian devil (Sarcophilus harrisii) from clade Metatheria, platypus  
 
(Ornithorhynchus anatinus), chicken (Gallus gallus) and lizard (Anolis carolinensis) or  
 
painted turtle (Chrysemys picta bellii) from clade Sauria, clawed frog (Xenopus laevis or  
 
Xenopus tropicalis), coelacanth (Latimeria chalumnae), either zebrafish (Danio rerio),  
 
Tetraodon (Tetraodon nigroviridis), or Fugu (Takifugu rubripes) from clade  
 
Clupeocephala, lancelet (Branchiostoma floridae), and sea urchin (Strongylocentrotus  
 
purpuratus) were included in our initial alignments. RAD50 and RAD51 did not reach  
 
three substitutions per position for their individual pMSA using the preceding organisms,  
 
so orthologous protein sequences from the model organisms Drosophila melanogaster,  
 
Caenorhabditis elegans, Saccharomyces cerevisiae, Schizosaccharomyces pombe, and  
 
Arabidopsis thaliana were added until three substitutions per position was achieved. 
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Ortholog sequences downloaded from Genbank were aligned using the expresso  
 
extension of T-Coffee to create the initial pMSA13,14. These initial alignments were  
 
checked by hand in Geneious v7.1.4 (http://www.geneious.com) for anomalies that might  
 
be attributed to gene model errors rather than actual sequence divergence. Potential  
 
anomalies were corrected by reference to, and gene re-prediction from, genomic DNA  
 




Protein multiple sequence alignment depth determination 
 
We counted substitutions in each alignment by using Protpars from PHYLIP  
 
v3.6915 with a constrained phylogeny to make a maximum parsimony estimate of the  
 
number of substitutions that occurred for each organism in the underlying phylogeny. In  
 
order to create a distance for MAPP, we used Protdist to establish a distance matrix for  
 
protein sequences using maximum likelihood estimates with a constrained phylogeny  
 
followed by Fitch to generate a phylogenetic tree under the additive tree model. The  
 
pathway-wide concatenated pMSA’s distances were calculated from the sum of  
 
substitutions and protein lengths at each node. The complete alignments, phylogenetic  
 






To assess evidence of risk from the case-control frequency distribution of protein- 
 
truncating variants (T), known or very likely spliceogenic splice-junction variants (SJV),  
 
and rare missense substitutions (rMS), we constructed a table with one entry per subject;  
 
the variants per subject; and annotations for whether the variant was in a key functional  
 
domain, its frequency, as well as study center, case-control status, race/ethnicity, and age  
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for the subject. For the subjects who carried more than one rare variant of interest, only  
 
the most deleterious score was considered. For each of the missense analysis programs,  
 
we toggled the program's severity score from a very relaxed to a very stringent value,  
 
repeatedly estimating two ORs as the stringency increased: the OR for subjects that  
 
carried one or more rMS at or above the score (and no T+SJV), and the OR for subjects  
 
who carried a rMS that was below the score (and carried neither a T+SJV nor a higher  
 
scoring rMS)(Figure A.1). From this analysis, we determined a threshold severity score  
 








This pathway-wide pMSA reached 3.66 substitutions per position with sequences  
 
from Human through Xenopus (Table A.1). For variant evaluation, we then adjusted our  
 
pMSAs to three depths: Human through Platypus (mammals only), Human through  
 
Xenopus (pathway-wide 3S/P depth), and Human through the organism required for 3S/P  
 
for each individual gene (gene-specific 3S/P depth). Although we were able to find a  
 
score for 3S/P such that the average OR ≥2.5 for the more severe variants, we were not  
 






It was interesting that neither Align-GVGD nor MAPP was able to achieve an  
 
OR≥2.5 with a pMSA that consisted of only mammals (Human through Platypus) nor the  
 
pathway-wide depth (Human through Xenopus), suggesting that these sequences,  
 
although generally more complete than the more distant organisms, do not offer an  
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adequate amount of variation to delineate variants. All of the missense analysis programs  
 
performed similarly, as determined by AUC (Table A.2, Figure A.2), this apparent  
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Table A.2. ROC curve estimates for each variant classifier 
Variant Classifier: 
pMSA depth Observation 
ROC 
Area Std. Err. 
Asymptotic Normal 
95% Confidence Interval 
Align-GVGD: Ma 302 0.5746 0.0323 0.51135 0.63787 
Align-GVGD: 3 S/Pb 302 0.5829 0.0303 0.52355 0.64233 
Align-GVGD: Xc 302 0.5716 0.0324 0.50816 0.63512 
MAPP: Ma 302 0.5685 0.036 0.49799 0.63907 
MAPP: 3 S/Pb 302 0.5883 0.0356 0.51848 0.65809 
MAPP: Xe 302 0.5823 0.0362 0.51137 0.65329 
CADD 302 0.5989 0.348 0.53073 0.66717 
Polyphen2 302 0.5923 0.0337 0.52631 0.65825 
aM=Mammals: Human through Ornithorynchus anatinus pMSA depth; b3 S/P=3 
substitutions per position: Human through 3 substitutions per position pMSA depth, 
which was different for each gene: ATM, Brachiostoma floridae; BARD1, Xenopus; 
CHEK2, Latimeria chalumnae; MRE11A, Branchiostoma floridae; NBN, Anolis 
carolinensis; RAD50, Drosophila melanogaster; RAD51, Arabidopsis thaliana; RINT1, 
Strongylocentrotus purpuratus; XRCC2, Danio rerio; cX=Xenopus: Human through 
Xenopus pMSA depth. dNC=noncurated: Human through Ornithorynchus anatinus, 
without hand-curation pMSA depth; eX=Xenopus: Human through Xenopus pMSA depth, 
excluding Anolis carolinensis orthologs.    
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Figure A.1. Observed OR and thresholds for each missense substitution analysis program. 
The observed OR for the carriers of rMS of both the “above” and “below” groups for 
each severity threshold tested with A) MAPP, and B) Align-GVGD, adjusting for 
race/ethnicity and study center. Vertical lines are indicative of the threshold for which the 

















































































































Figure A.2. ROC curves for each variant classifier. 
a
M=Mammals: Human through 
Ornithorynchus anatinus pMSA depth; 
b
3M=3 substitutions per position: Human through 
3M pMSA depth, which was different for each gene: ATM, Brachiostoma floridae; 
BARD1, Xenopus; CHEK2, Latimeria chalumnae; MRE11A, Branchiostoma floridae; 
NBN, Anolis carolinensis; RAD50, Drosophila melanogaster; RAD51, Arabidopsis 
thaliana; RINT1, Strongylocentrotus purpuratus; XRCC2, Danio rerio; 
c
X=Xenopus: 
Human through Xenopus pMSA depth. 
d
NC=noncurated: Human through Ornithorynchus 
anatinus, without hand-curation pMSA depth; 
e
X=Xenopus: Human through Xenopus 
pMSA depth, excluding Anolis carolinensis orthologs.   
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